Your comments back up what I stated. Twenty seven months is considered a long remission for a relapsed myeloma patient. Wife101's husband had a seven-year drug free remission. That projects to 3.5 years - about twice as long as the 21 months you mention for Ninlaro, Revlimid, and dexamethasone.
You wrote:
I’m not sure that the toxicity of the second stem cell transplant is worth it, especially if there is ongoing maintenance regardless of which treatment you select.
Why do you have to use maintenance? I never used any maintenance. I used high-dose therapy twice in 2011 and have no long-term side effects at this time. Note the Mayo Clinic study.
"Auto-SCT2 has an initial risk of significant toxicity but it may also provide the potential of having a prolonged time off treatment in appropriately selected patients. On the other hand, novel agents such as thalidomide, lenalidomide or bortezomib are associated with a higher risk of grade III or IV toxicities such as neuropathy, myelosuppression and thrombosis."
If the novel agents are associated with a higher risk of grade 3 or 4 side effects, wouldn't that be the therapy to worry about with regard to toxicity?
Mark